Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immix Biopharma, Inc.

1.71
+0.03001.79%
Volume:11.33K
Turnover:19.17K
Market Cap:47.40M
PE:-2.24
High:1.71
Open:1.69
Low:1.69
Close:1.68
Loading ...

Company Profile

Company Name:
Immix Biopharma, Inc.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
- -
Office Location:
11400 West Olympic Boulevard,Suite 200,Los Angeles,California,United States
Zip Code:
90064
Fax:
- -
Introduction:
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Directors

Name
Position
Ilya Rachman
Chief Executive Officer and Chairman
Gabriel Morris
Chief Financial Officer and Director
Carey Ng
Director
Helen C. Adams
Director
Jane M. Buchan
Director
Jason Hsu
Director
Magda Marquet
Director

Shareholders

Name
Position
Ilya Rachman
Chief Executive Officer and Chairman
Gabriel Morris
Chief Financial Officer and Director
Graham Ross
Acting Chief Medical Officer and Head of Clinical Development
Nandan Oza
Head of Chemistry, Manufacturing, and Control
Vladimir Torchilin
Scientific Co-Founder